Regeneron Pharmaceuticals (REGN) 422.13 $REGN
3 Little-Known Stocks I'm Glad I Bought
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 08, 12:04PM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks isn't for the faint of heart. The industry's jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor's...
JNJ: 100.11 (-2.41), INSY: 57.69 (+0.08), PTLA: 41.72 (-0.13), PFE: 33.97 (-0.50), OPHT: 53.19 (-0.29), BMY: 65.12 (-0.93), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Complexities Of Eye Care Drive Strong Moats
Morningstar - at Seeking Alpha - Fri Mar 06, 4:10PM CST
By David Krempa, CFA We see attractive growth opportunities for the ophthalmology market. We see strong competitive advantages in the $50 billion ophthalmology market as a result of manufacturing complexity, strict government regulation, limited...
AGN: 233.51 (-1.90), ABT: 46.50 (-0.94), JNJ: 100.11 (-2.41), VRX: 198.71 (-5.24), AKRX: 49.83 (-1.05), LUX: 60.94 (-0.30), COO: 180.26 (+15.00), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Regeneron Jumps Ahead In $10 Billion Race For Next Generation Cardio Drugs
Cheryl Swanson - at Seeking Alpha - Fri Mar 06, 1:35PM CST
PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), SNY: 47.42 (-0.94), REGN: 422.13 (-6.82)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), GPRO: 40.13 (-0.95), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), KMB: 106.82 (-1.64), LLTC: 47.65 (-0.72), BMY: 65.12 (-0.93), ALKS: 68.19 (-3.03), CHRS: 27.48 (-2.23), CELG: 118.03 (-2.68), W: 28.81 (+1.03), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), LH: 121.70 (-1.58), MCD: 97.13 (-1.98), REGN: 422.13 (-6.82), BABA: 84.40 (-1.70)
Must-See Charts: How to Trade 5 Big Stocks for Big Gains
at The Street - Thu Mar 05, 6:00AM CST
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
MDLZ: 35.22 (-1.29), GIS: 52.13 (-1.15), REGN: 422.13 (-6.82), SYK: 90.07 (-2.92), EQR: 75.03 (-2.30)
Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More
at The Street - Thu Mar 05, 4:34AM CST
Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), W: 28.81 (+1.03), HON: 101.87 (-1.26), GILD: 101.81 (-1.61), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), HON: 101.87 (-1.26), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), JNJ: 100.11 (-2.41), W: 28.81 (+1.03), SCTY: 50.45 (-1.32), CMG: 658.68 (-11.81), RCPT: 140.09 (-1.10), FL: 59.37 (+2.34), REGN: 422.13 (-6.82), HYH: 46.26 (+0.79), CY: 15.10 (-0.40), SWKS: 90.75 (-0.80), VFC: 74.49 (-1.58), NXPI: 98.48 (-0.19), ALKS: 68.19 (-3.03), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), URBN: 38.89 (+0.15), HAIN: 61.66 (-1.03), FSLR: 60.61 (-1.05), GOGO: 20.21 (+0.14), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), MCD: 97.13 (-1.98), STM: 9.18 (-0.13), DST: 106.03 (+0.16), BIG: 48.52 (+0.70), AVGO: 127.89 (-2.68)
Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Sarcopenia Therapeutics Pipeline Review 2015 - 9 Companies & 12 Drug Profiles
M2 - Mon Mar 02, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/tthlfw/sarcopenia) has announced the addition of the "Sarcopenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Calzada Limited - Cytokinetics, Inc. - GlaxoSmithKline plc - Myos Corporation - Neurotune AG - Novartis AG - PsiOxus Therapeutics, Ltd. - Regeneron Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - AOD-9604 - bimagrumab - CK-2066260 - MT-102 - NEP-28 - NT-1654 - Protein for Musculoskeletal Disorders - Recombinant Protein for Sarcopenia - REGN-1033 - S-107 - Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia For more information visit http://www.researchandmarkets.com/research/tthlfw/sarcopenia
CYTK: 7.80 (-0.11), GSK: 46.73 (-0.87), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
A Quick Review Of The Asthma Market
Declan Fallon - at Seeking Alpha - Fri Feb 27, 9:26AM CST
PRGO: 156.83 (-3.17), AZN: 66.27 (-1.91), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72), TEVA: 56.40 (-0.11), IMNP: 1.73 (-0.03), THRX: 19.60 (-0.26), GSK: 46.73 (-0.87), XNCR: 15.33 (-0.67), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Sanofi assumes all Zaltrap development from Regeneron
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:01AM CST
SNY: 47.42 (-0.94), REGN: 422.13 (-6.82)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Feb 26, 10:07AM CST
Is Pharmacyclics (PCYC) up for sale? J&J and Novartis are rumored to be interested in acquiring the company.
VRTX: 126.34 (-0.62), PCYC: 254.56 (+0.34), VVUS: 2.79 (-0.08), AMGN: 154.88 (-4.72), ALKS: 68.19 (-3.03), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
New indication for Regeneron's Eylea cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 7:59AM CST
REGN: 422.13 (-6.82)
'Mad Money' Lightning Round: I Believe in Alcoa and Its CEO
at The Street - Thu Feb 26, 5:00AM CST
Cramer likes Spansion and Taiwan Semiconductor but isn't crazy about Theravance and SanDisk.
CY: 15.10 (-0.40), SWIR: 35.24 (-1.14), SWKS: 90.75 (-0.80), TSM: 24.09 (-0.37), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), AA: 14.48 (+0.10), OPK: 14.11 (-0.21), THRX: 19.60 (-0.26), REGN: 422.13 (-6.82), SNDK: 80.65 (-1.86), BABA: 84.40 (-1.70), CODE: 36.99 (-0.98)
SanDisk Has Disappointed Twice - Cramer's Lightning Round (2/25/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Feb 26, 4:51AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, February 25. Bullish Calls: Spansion (NYSE: CODE ): "I like Spansion because of the merger with Cypress Semiconductor (NASDAQ: CY ). I want you to...
SWIR: 35.24 (-1.14), CY: 15.10 (-0.40), BMRN: 113.77 (+0.27), SWKS: 90.75 (-0.80), TSM: 24.09 (-0.37), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), AA: 14.48 (+0.10), OPK: 14.11 (-0.21), TBPH: 20.23 (-0.52), SNDK: 80.65 (-1.86), AVGO: 127.89 (-2.68), REGN: 422.13 (-6.82), CODE: 36.99 (-0.98), BABA: 84.40 (-1.70)
Jim Cramer's 'Mad Money' Recap: Kicking Out Value for Old-Fashioned Growth Stocks
at The Street - Wed Feb 25, 7:01PM CST
Investors have collectively decided that they're OK with a little more risk, Cramer says.
GE: 25.42 (-0.40), BX: 38.75 (-0.39), INTC: 33.19 (-0.54), LQ: 22.50 (-0.05), SBUX: 92.21 (-1.42), YHOO: 43.44 (-0.72), OPK: 14.11 (-0.21), CMG: 658.68 (-11.81), GOOGL: 572.90 (-8.53), LOW: 73.51 (-1.05), THRX: 19.60 (-0.26), MSFT: 42.36 (-0.75), REGN: 422.13 (-6.82), CODE: 36.99 (-0.98), KO: 41.52 (-0.88), SWIR: 35.24 (-1.14), CY: 15.10 (-0.40), AMZN: 380.09 (-7.74), HD: 114.45 (-1.46), FEYE: 42.83 (-1.08), SWKS: 90.75 (-0.80), FB: 80.00 (-1.21), TSM: 24.09 (-0.37), HPQ: 33.18 (-0.82), CELG: 118.03 (-2.68), NFLX: 454.12 (-13.53), AA: 14.48 (+0.10), TOL: 36.92 (-1.00), SNDK: 80.65 (-1.86), CRM: 64.56 (-1.03), BABA: 84.40 (-1.70)
Billions on the Line in the Next Drug Pricing War
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 24, 7:02AM CST
Source: Gilead Sciences One win whets the appetite for another. That certainly seems to be the case for the nation's two largest pharmacy benefits managers, Express Scripts and CVS Health . After scoring a victory in bringing hepatitis C...
ESRX: 82.27 (-2.01), GILD: 101.81 (-1.61), CVS: 101.90 (-1.46), REGN: 422.13 (-6.82)
Market Is Not In A Bubble - Cramer's Mad Money (2/23/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 24, 6:40AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, February 23. With Nasdaq near all-time highs after 15 years, Cramer is listening to people talk about a new bubble forming. He said one of the good things about...
TSLA: 193.88 (-6.75), VRX: 198.71 (-5.24), CYBR: 59.78 (-3.09), AMGN: 154.88 (-4.72), INTC: 33.19 (-0.54), GOOG: 567.68 (-7.65), ORCL: 42.38 (-1.42), CELG: 118.03 (-2.68), AGEN: 5.11 (-0.17), T: 33.48 (-0.52), CTB: 37.05 (-0.43), JPM: 60.89 (-1.11), GILD: 101.81 (-1.61), HZNP: 21.91 (+1.07), GM: 36.84 (-0.77), GOOGL: 572.90 (-8.53), MSFT: 42.36 (-0.75), VZ: 48.29 (-0.63), DOW: 47.94 (-0.95), AAPL: 126.60 (+0.19), REGN: 422.13 (-6.82), CSCO: 28.92 (-0.38)
'Mad Money' Lightning Round: Buy Enbridge Energy Partners
at The Street - Tue Feb 24, 5:00AM CST
Cramer isn't excited by Yahoo!, would buy more Xcel Energy and likes Cisco over Arris Group.
XEL: 33.65 (-1.28), BCRX: 10.05 (-0.18), BX: 38.75 (-0.39), WFC: 54.59 (-0.25), EEP: 38.43 (-0.17), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), APO: 22.28 (-0.42), ISIS: 70.44 (-1.32), JPM: 60.89 (-1.11), ARRS: 28.54 (-0.46), KATE: 32.82 (-0.44), CSCO: 28.92 (-0.38), REGN: 422.13 (-6.82)
Enbridge Energy Partners Is Cheap - Cramer's Lightning Round (2/23/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 24, 4:53AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, February 23. Bullish Calls: Enbridge Energy Partners (NYSE: EEP ): "I think this stock is way too cheap. I like the 5% yield. I think the management...
XEL: 33.65 (-1.28), BCRX: 10.05 (-0.18), BMRN: 113.77 (+0.27), BX: 38.75 (-0.39), KORS: 65.98 (-1.16), EEP: 38.43 (-0.17), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), COH: 41.43 (-0.68), APO: 22.28 (-0.42), JPM: 60.89 (-1.11), ISIS: 70.44 (-1.32), ARRS: 28.54 (-0.46), KATE: 32.82 (-0.44), REGN: 422.13 (-6.82), CSCO: 28.92 (-0.38)
3 Little-Known Stocks I'm Glad I Bought
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 08, 12:04PM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks isn't for the faint of heart. The industry's jaw-dropping pops and drops can be so dramatic as to suit these stocks only the most speculative portion of an investor's...
JNJ: 100.11 (-2.41), INSY: 57.69 (+0.08), PTLA: 41.72 (-0.13), PFE: 33.97 (-0.50), OPHT: 53.19 (-0.29), BMY: 65.12 (-0.93), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Complexities Of Eye Care Drive Strong Moats
Morningstar - at Seeking Alpha - Fri Mar 06, 4:10PM CST
By David Krempa, CFA We see attractive growth opportunities for the ophthalmology market. We see strong competitive advantages in the $50 billion ophthalmology market as a result of manufacturing complexity, strict government regulation, limited...
AGN: 233.51 (-1.90), ABT: 46.50 (-0.94), JNJ: 100.11 (-2.41), VRX: 198.71 (-5.24), AKRX: 49.83 (-1.05), LUX: 60.94 (-0.30), COO: 180.26 (+15.00), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Regeneron Jumps Ahead In $10 Billion Race For Next Generation Cardio Drugs
Cheryl Swanson - at Seeking Alpha - Fri Mar 06, 1:35PM CST
PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), SNY: 47.42 (-0.94), REGN: 422.13 (-6.82)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), GPRO: 40.13 (-0.95), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), KMB: 106.82 (-1.64), LLTC: 47.65 (-0.72), BMY: 65.12 (-0.93), ALKS: 68.19 (-3.03), CHRS: 27.48 (-2.23), CELG: 118.03 (-2.68), W: 28.81 (+1.03), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), LH: 121.70 (-1.58), MCD: 97.13 (-1.98), REGN: 422.13 (-6.82), BABA: 84.40 (-1.70)
Must-See Charts: How to Trade 5 Big Stocks for Big Gains
at The Street - Thu Mar 05, 6:00AM CST
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
MDLZ: 35.22 (-1.29), GIS: 52.13 (-1.15), REGN: 422.13 (-6.82), SYK: 90.07 (-2.92), EQR: 75.03 (-2.30)
Jim Cramer's Top Takeaways: Wayfair, Honeywell, Halyard Health, More
at The Street - Thu Mar 05, 4:34AM CST
Cramer says that Honeywell is his one of his favorite industrial stocks and that the biotech sector is filled with strong buys, including Regeneron and Celgene.
HYH: 46.26 (+0.79), RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), W: 28.81 (+1.03), HON: 101.87 (-1.26), GILD: 101.81 (-1.61), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 89.94 (-0.65), BIIB: 417.63 (-7.98), BMRN: 113.77 (+0.27), PCYC: 254.56 (+0.34), HON: 101.87 (-1.26), KMB: 106.82 (-1.64), RRD: 19.48 (+0.21), JNJ: 100.11 (-2.41), W: 28.81 (+1.03), SCTY: 50.45 (-1.32), CMG: 658.68 (-11.81), RCPT: 140.09 (-1.10), FL: 59.37 (+2.34), REGN: 422.13 (-6.82), HYH: 46.26 (+0.79), CY: 15.10 (-0.40), SWKS: 90.75 (-0.80), VFC: 74.49 (-1.58), NXPI: 98.48 (-0.19), ALKS: 68.19 (-3.03), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), URBN: 38.89 (+0.15), HAIN: 61.66 (-1.03), FSLR: 60.61 (-1.05), GOGO: 20.21 (+0.14), ISIS: 70.44 (-1.32), GILD: 101.81 (-1.61), MCD: 97.13 (-1.98), STM: 9.18 (-0.13), DST: 106.03 (+0.16), BIG: 48.52 (+0.70), AVGO: 127.89 (-2.68)
Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Sarcopenia Therapeutics Pipeline Review 2015 - 9 Companies & 12 Drug Profiles
M2 - Mon Mar 02, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/tthlfw/sarcopenia) has announced the addition of the "Sarcopenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Calzada Limited - Cytokinetics, Inc. - GlaxoSmithKline plc - Myos Corporation - Neurotune AG - Novartis AG - PsiOxus Therapeutics, Ltd. - Regeneron Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - AOD-9604 - bimagrumab - CK-2066260 - MT-102 - NEP-28 - NT-1654 - Protein for Musculoskeletal Disorders - Recombinant Protein for Sarcopenia - REGN-1033 - S-107 - Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Small Molecules to Inhibit JAK3 for Sarcopenia and Cachexia For more information visit http://www.researchandmarkets.com/research/tthlfw/sarcopenia
CYTK: 7.80 (-0.11), GSK: 46.73 (-0.87), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
A Quick Review Of The Asthma Market
Declan Fallon - at Seeking Alpha - Fri Feb 27, 9:26AM CST
PRGO: 156.83 (-3.17), AZN: 66.27 (-1.91), MRK: 56.84 (-1.14), AMGN: 154.88 (-4.72), TEVA: 56.40 (-0.11), IMNP: 1.73 (-0.03), THRX: 19.60 (-0.26), GSK: 46.73 (-0.87), XNCR: 15.33 (-0.67), REGN: 422.13 (-6.82), NVS: 97.46 (-1.49)
Sanofi assumes all Zaltrap development from Regeneron
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:01AM CST
SNY: 47.42 (-0.94), REGN: 422.13 (-6.82)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Feb 26, 10:07AM CST
Is Pharmacyclics (PCYC) up for sale? J&J and Novartis are rumored to be interested in acquiring the company.
VRTX: 126.34 (-0.62), PCYC: 254.56 (+0.34), VVUS: 2.79 (-0.08), AMGN: 154.88 (-4.72), ALKS: 68.19 (-3.03), REGN: 422.13 (-6.82), CELG: 118.03 (-2.68)
New indication for Regeneron's Eylea cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 7:59AM CST
REGN: 422.13 (-6.82)
'Mad Money' Lightning Round: I Believe in Alcoa and Its CEO
at The Street - Thu Feb 26, 5:00AM CST
Cramer likes Spansion and Taiwan Semiconductor but isn't crazy about Theravance and SanDisk.
CY: 15.10 (-0.40), SWIR: 35.24 (-1.14), SWKS: 90.75 (-0.80), TSM: 24.09 (-0.37), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), AA: 14.48 (+0.10), OPK: 14.11 (-0.21), THRX: 19.60 (-0.26), REGN: 422.13 (-6.82), SNDK: 80.65 (-1.86), BABA: 84.40 (-1.70), CODE: 36.99 (-0.98)
SanDisk Has Disappointed Twice - Cramer's Lightning Round (2/25/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Feb 26, 4:51AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, February 25. Bullish Calls: Spansion (NYSE: CODE ): "I like Spansion because of the merger with Cypress Semiconductor (NASDAQ: CY ). I want you to...
SWIR: 35.24 (-1.14), CY: 15.10 (-0.40), BMRN: 113.77 (+0.27), SWKS: 90.75 (-0.80), TSM: 24.09 (-0.37), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), AA: 14.48 (+0.10), OPK: 14.11 (-0.21), TBPH: 20.23 (-0.52), SNDK: 80.65 (-1.86), AVGO: 127.89 (-2.68), REGN: 422.13 (-6.82), CODE: 36.99 (-0.98), BABA: 84.40 (-1.70)
Jim Cramer's 'Mad Money' Recap: Kicking Out Value for Old-Fashioned Growth Stocks
at The Street - Wed Feb 25, 7:01PM CST
Investors have collectively decided that they're OK with a little more risk, Cramer says.
GE: 25.42 (-0.40), BX: 38.75 (-0.39), INTC: 33.19 (-0.54), LQ: 22.50 (-0.05), SBUX: 92.21 (-1.42), YHOO: 43.44 (-0.72), OPK: 14.11 (-0.21), CMG: 658.68 (-11.81), GOOGL: 572.90 (-8.53), LOW: 73.51 (-1.05), THRX: 19.60 (-0.26), MSFT: 42.36 (-0.75), REGN: 422.13 (-6.82), CODE: 36.99 (-0.98), KO: 41.52 (-0.88), SWIR: 35.24 (-1.14), CY: 15.10 (-0.40), AMZN: 380.09 (-7.74), HD: 114.45 (-1.46), FEYE: 42.83 (-1.08), SWKS: 90.75 (-0.80), FB: 80.00 (-1.21), TSM: 24.09 (-0.37), HPQ: 33.18 (-0.82), CELG: 118.03 (-2.68), NFLX: 454.12 (-13.53), AA: 14.48 (+0.10), TOL: 36.92 (-1.00), SNDK: 80.65 (-1.86), CRM: 64.56 (-1.03), BABA: 84.40 (-1.70)
Billions on the Line in the Next Drug Pricing War
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 24, 7:02AM CST
Source: Gilead Sciences One win whets the appetite for another. That certainly seems to be the case for the nation's two largest pharmacy benefits managers, Express Scripts and CVS Health . After scoring a victory in bringing hepatitis C...
ESRX: 82.27 (-2.01), GILD: 101.81 (-1.61), CVS: 101.90 (-1.46), REGN: 422.13 (-6.82)
Market Is Not In A Bubble - Cramer's Mad Money (2/23/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 24, 6:40AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, February 23. With Nasdaq near all-time highs after 15 years, Cramer is listening to people talk about a new bubble forming. He said one of the good things about...
TSLA: 193.88 (-6.75), VRX: 198.71 (-5.24), CYBR: 59.78 (-3.09), AMGN: 154.88 (-4.72), INTC: 33.19 (-0.54), GOOG: 567.68 (-7.65), ORCL: 42.38 (-1.42), CELG: 118.03 (-2.68), AGEN: 5.11 (-0.17), T: 33.48 (-0.52), CTB: 37.05 (-0.43), JPM: 60.89 (-1.11), GILD: 101.81 (-1.61), HZNP: 21.91 (+1.07), GM: 36.84 (-0.77), GOOGL: 572.90 (-8.53), MSFT: 42.36 (-0.75), VZ: 48.29 (-0.63), DOW: 47.94 (-0.95), AAPL: 126.60 (+0.19), REGN: 422.13 (-6.82), CSCO: 28.92 (-0.38)
'Mad Money' Lightning Round: Buy Enbridge Energy Partners
at The Street - Tue Feb 24, 5:00AM CST
Cramer isn't excited by Yahoo!, would buy more Xcel Energy and likes Cisco over Arris Group.
XEL: 33.65 (-1.28), BCRX: 10.05 (-0.18), BX: 38.75 (-0.39), WFC: 54.59 (-0.25), EEP: 38.43 (-0.17), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), APO: 22.28 (-0.42), ISIS: 70.44 (-1.32), JPM: 60.89 (-1.11), ARRS: 28.54 (-0.46), KATE: 32.82 (-0.44), CSCO: 28.92 (-0.38), REGN: 422.13 (-6.82)
Enbridge Energy Partners Is Cheap - Cramer's Lightning Round (2/23/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 24, 4:53AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, February 23. Bullish Calls: Enbridge Energy Partners (NYSE: EEP ): "I think this stock is way too cheap. I like the 5% yield. I think the management...
XEL: 33.65 (-1.28), BCRX: 10.05 (-0.18), BMRN: 113.77 (+0.27), BX: 38.75 (-0.39), KORS: 65.98 (-1.16), EEP: 38.43 (-0.17), CELG: 118.03 (-2.68), YHOO: 43.44 (-0.72), COH: 41.43 (-0.68), APO: 22.28 (-0.42), JPM: 60.89 (-1.11), ISIS: 70.44 (-1.32), ARRS: 28.54 (-0.46), KATE: 32.82 (-0.44), REGN: 422.13 (-6.82), CSCO: 28.92 (-0.38)
